Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC)

Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 474e8fcdeec6cf1fdedea7a1cfe2475cdc703270
First added on: Feb 08, 2025